- Home
- GANX vs RNXT Comparison
GANX vs RNXT Comparison
Compare GANX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GANX | RNXT |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 79.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GANX | RNXT |
|---|---|---|
| Price | $1.24 | $1.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $7.20 | $7.13 |
| AVG Volume (30 Days) | ★ 494.7K | 483.8K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.46 | 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | $55,180.00 | ★ $1,123,000.00 |
| Revenue This Year | N/A | $244.84 |
| Revenue Next Year | N/A | $195.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $1.21 | $0.70 |
| 52 Week High | $4.34 | $2.59 |
Technical Indicators
Market Signals| Indicator | GANX | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 23.19 | 34.70 |
| Support Level | N/A | $0.83 |
| Resistance Level | $2.01 | $1.28 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 9.51 | 13.64 |
Price Performance
Historical ComparisonAbout GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.